PTEN Hamartoma Tumor Syndrome Evidence-Backed Research Fallback

Provider Attempts

The primary deep-research provider attempts did not return usable research documents within bounded command budgets. The review-requested longer command, timeout 300s just research-disorder openai PTEN_Hamartoma_Tumor_Syndrome, also timed out with exit code 124 after starting research/PTEN_Hamartoma_Tumor_Syndrome-deep-research-openai.md. No partial provider artifact was left on disk. The curation therefore uses a manual evidence-backed synthesis from fetched structured and literature caches.

Evidence Synthesis

ORPHA:306498 defines PTEN hamartoma tumor syndrome as a rare skin tumor/hamartoma disease group characterized by germline PTEN mutation, hamartomas, overgrowth, and increased neoplasia risk. The same Orphanet record supplies the autosomal dominant inheritance, worldwide prevalence band, and the PHTS group scope that includes Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, Proteus-like syndrome, Lhermitte-Duclos disease, and SOLAMEN syndrome.

PMID:18781191 anchors the core molecular mechanism: PTEN loss releases negative regulation of PI3K/AKT/mTOR signaling, increasing cellular growth, migration, proliferation, and survival. The YAML models this as PTEN loss and PI3K-AKT-mTOR activation, with downstream hamartomatous tissue overgrowth and multiorgan cancer predisposition. These mechanism nodes are intentionally atomic so the graph separates molecular signaling from tissue-level and clinical consequences.

PMID:20301661 provides the GeneReviews clinical frame for PHTS. It supports the PHTS subtype scope, the typical Cowden presentation with macrocephaly, trichilemmomas, papillomatous papules, and benign/malignant tumors, the BRRS presentation with macrocephaly, intestinal hamartomatous polyposis, lipomas, and pigmented macules, molecular diagnosis by heterozygous germline PTEN pathogenic variant testing, autosomal dominant counseling, cascade testing, and surveillance recommendations for thyroid, skin, breast, endometrial, colon, and renal cancer risk.

PMID:33140411 is the main human clinical cancer-risk source. It supports the neoplastic phenotype set for breast carcinoma, endometrial carcinoma, thyroid carcinoma, renal neoplasm, colorectal cancer, and melanoma, with cumulative lifetime risk ranges drawn from cohort studies. The cancer-risk phenotypes and surveillance treatment entry are therefore modeled as human clinical evidence rather than mechanistic inference alone.

PMID:31609537 and PMID:26564076 cover the childhood and genomic-era neurodevelopmental spectrum. They support macrocephaly, developmental delay, autism spectrum manifestations, and broad neurodevelopmental overgrowth in PHTS. PMID:26564076 also supports the genetic-counseling note that at least 10% and perhaps as many as 44% of cases arise from de novo PTEN mutation.

PMID:35594551 and clinicaltrials:NCT02991807 support the investigational everolimus entry. Everolimus targets mTOR overactivity and was studied in a randomized phase II PHTS trial for neurocognitive symptoms, but the cited trial did not meet the primary efficacy endpoint; it is therefore represented as investigational pharmacotherapy rather than standard care.

Scope Confirmation

The YAML intentionally centers on the syndrome-group PHTS entry rather than the already-curated Cowden syndrome file. It includes PTEN as the defining causative gene, Orphanet/GeneReviews subtype coverage, OAK-verified MONDO subtype bindings, representative non-malignant manifestations, major cancer-risk phenotypes, PTEN molecular testing, surveillance, genetic counseling, and the completed everolimus trial. Reviewer-suggested subtype MONDO IDs were checked with OAK and found to resolve to unrelated disorders locally, so the YAML uses the verified local MONDO IDs instead.